Open AccessDecitabine: An effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia
Author(s) -
Xianqi Feng,
Xiangyun Chen,
Shumin Nie,
Yung-Fu Chang,
Fanjun Meng,
Jingjing Zhou,
Chunxia Mao,
Tianlan Li,
Xinfeng Yan,
Jiuzuo Huang,
Shanshan Liu,
Guoquan Yan,
Shuxin Xiao
Publication year - 2019
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.204849
Subject(s) - decitabine , medicine , myelodysplastic syndromes , myeloid leukemia , international prognostic scoring system , anemia , incidence (geometry) , leukemia , oncology , bone marrow , biochemistry , gene expression , chemistry , physics , optics , dna methylation , gene
Decitabine is reported to be valuable in treating multiple malignant blood diseases. However, the application of decitabine in myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML) has not been fully examined. Thus, our study aimed to investigate the clinical efficacy and safety of decitabine in treating such patients.